Trump Deal with Eli Lilly and Novo Nordisk Expands Access to GLP-1 Drugs for Millions

President Donald Trump announced this Thursday, November 6, 2025, an agreement with the companies Eli Lilly and Novo Nordisk to reduce the prices of the medicines Wegovy and Zepbound. The measure aims to expand access to these popular weight loss treatments, which currently cost more than US$1,000 per month. The announcement took place during a press conference at the White House in Washington, and is part of efforts to align drug costs in the United States with those in other developed countries.
Under the pact, Medicare patients will pay a maximum of $50 copays for approved doses of GLP-1, including uses for diabetes and obesity. For those who pay in cash, starting prices vary from US$149 to US$350, depending on the dosage, via the TrumpRx platform. The initiative responds to the growing demand for these drugs, which help reduce cardiovascular risks and treat sleep apnea.
Eli Lilly and Novo Nordisk agreed to waive pharmaceutical tariffs for three years in return. Administration officials estimate that millions of beneficiaries of federal programs qualify as long as they meet criteria such as severe obesity or comorbidities such as heart or kidney disease.
Price cut details
Listed prices for Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy exceed $1,000 monthly without insurance. With the agreement, direct payment options drop to $299 for the initial dose of Zepbound and $250 for Wegovy over two years.
Patients without coverage pay less via company websites, such as LillyDirect and NovoCare. Retailers like Costco and Walmart already offer Wegovy and Zepbound for $499 on cash purchases.
The TrumpRx program, a government website, will facilitate purchases at these values until the end of 2025. For Medicaid, states will decide on adherence, with no copayment for beneficiaries.
Medicare Expansion
Medicare prohibits exclusive coverage for weight loss, but the agreement creates a pilot for obesity with associated conditions. Patients with cardiac risk or apnea now access Wegovy and Zepbound.
Criteria include body mass index above 30 or overweight with comorbidities. Full coverage begins in mid-2026, after adjustments to annual premiums.
Health policy experts question the scope, as US$250 a month still burdens many. Ovoluntary pact avoids formal negotiations of the Inflation Reduction Act.
Novo Nordisk plans to invest US$10 billion in the USA, reinforcing local production.
Oral formats under development
Initial doses of GLP-1 pills will cost $149 via Medicare or TrumpRx, pending FDA approval. Eli Lilly has requested priority voucher for acceleration.
No weight loss pill is approved, but studies are progressing. Novo Nordisk is testing an oral version of Wegovy, with a decision expected by December 2025.
These oral formats promise greater adherence than weekly injections. The administration prioritizes quick approvals to expand affordable options.
Diabetic patients already use Ozempic and Mounjaro covered, but the focus now is isolated obesity.
Context of the presidential initiative
Trump revived the “most favored nation” model by executive order in May 2025. The strategy compares international prices to pressure reductions.
Similar deals with Pfizer and AstraZeneca cut Medicaid costs for other drugs. The administration rejected previous expansion proposals under Biden.
Negotiations of the Inflation Reduction Law continue for 15 pharmaceuticals, including GLP-1s, with final prices until November 30th. These voluntary pacts complement the process.
The measure aligns with criticism of high costss in the USA, three times higher than in European nations.
Pharmaceutical reactions
Eli Lilly praised the collaboration in an official statement. The company focuses on innovative obesity pipelines, with 40% of new prescriptions via direct payment.
Novo Nordisk executives highlighted prolonged dialogues with the government. CEO Mike Doustdar emphasized broad access as a shared goal.
Both sign tariff exemption for three years. Local production gains momentum with investments.
The agreement benefits exports, balancing trade concessions.
Direct payment options
- Wegovy: $350 starting, reduces to $250 in 2027 via TrumpRx.
- Zepbound: $299 low dose, up to $449 high dose.
- Starting pills: $149 for all channels, post-approval.
- Medicare Copay: Maximum $50 for approved nominees.
- Medicaid: No copay, variable state membership.
These ranges apply to cash payers and federal insurance. Retailers maintain parallel discounts.
Approved clinical applications
Wegovy has been treating obesity with heart risks since 2024. Zepbound covers moderate to severe sleep apneabird.
Ozempic and Mounjaro focus on type 2 diabetes. They all use semaglutide or tirzepatide for glycemic regulation and weight loss.
Indications expand for cardiovascular prevention. Studies show a 20% reduction in cardiac events.
Off-label use for weight persists, but agreement prioritizes formal approvals.






